1. Introduction {#s0005}
===============

Several factors affect the development of cancer including the combination of environmental, and host factors. Inflammation has been linked and increased the risk for development different type of tumors such as gastric mucosal lymphoma, colon cancer, gastric cancer, and prostate cancer. Many factors lead to chronic inflammation such as microbial infections (e.g., *Helicobacter pylori* infection), autoimmune diseases (e.g., inflammatory bowel disease), inflammatory conditions (e.g., prostatitis), chemical compounds (e.g., ROS), or physical injuries (e.g., exposure to UV) ([@b0015], [@b0105], [@b0040], [@b0130]).

There are two cyclooxygenase COX enzymes, namely cyclooxygenase-1 COX-1, and cyclooxygenase-2 COX-2. The cytoprotection process in the gastrointestinal tract and normal renal function is regulated by the constitutive isozyme COX-1. COX-2 is a proactive, and short-lived enzyme; its expression occurs as a pro-inflammatory response. COX-2 is involved in prostaglandin biosynthesis in inflammatory cells of the central nervous system ([@b0135], [@b0085]). The activation of such enzymes stimulates intracellular signals (i.e., NF*κ*B ([@b0160], [@b0035]), p38, or MAPKs ([@b0060]), which modify pro-inflammatory cytokine expression e.g., interleukin 1 beta (IL1*β*) ([@b0050]), interleukin 6 (IL6) ([@b0170]), and tumor necrosis factor alpha (TNF-*α*) ([@b0165]). These signals combined with cell adhesion proteins and chemokines leads to the stimulation and activation of immune cells. Therefore, many researchers focus on developing novel and selective inhibitors of pro-inflammatory enzymes and cytokines.

Oxindole derivatives are known as anti-tumor agents due to their tyrosine kinase inhibitory property. Additionally, the oxindole scaffold exhibits promising structural features and a good bioactivity profile including antiviral, antimicrobial, and local anesthetic properties ([@b0075], [@b0140], [@b0175], [@b0065], [@b0145], [@b0180]). Therefore, these compounds may further the design of novel lead compounds with anti-inflammatory, and anticancer activities. Recently, one such compound, **JP-8g**, exhibited high efficacy against cancer, and inflammation ([@b0150], [@b0155]). Among synthetic compounds, oxindole gained attention as a potential anticancer drug. In this regard, compounds **SPX-F** ([@b0100]), and **4d** ([@b0025], [@b0020]) have exhibited efficacy for MDM2--p53 protein--protein interaction inhibitor and p53 reactivation in cancer cells ([Fig. 1](#f0005){ref-type="fig"}).Fig. 1Representative examples of spirooxindoles and benzo\[*b*\]furan scaffolds.

Benzo\[*b*\]furan is an interesting pharmacophore which exists in several synthetic and natural hits and has pharmaceutical applications ([@b0055]). Some publications report the benzo\[*b*\]furan moiety to inhibit activities of human immunodeficiency virus (HIV) and hepatitis C virus (HVC). In addition, it also has possessed as antioxidant, cytotoxic, anti-inflammatory (e.g. ailanthoidol), antitumor, antimicrobial, antiplasmodial and, antitubercular activities ([@b0055]) ([Fig. 1](#f0005){ref-type="fig"}).

A derivative of celecoxib based a benzo\[*b*\]furan moiety was reported to demonstrate selective activity against COX-2 ([@b0080]). In addition, new molecules containing rhodanine and benzofuran scaffolds were designed, synthesized, and reported to exhibit dual COX-2, and 5-LOX inhibitory potential. Recent patent survey reported as a review focused on the benzofuran inhibitors ([@b0070]).

In this study, a series of compounds having the oxindole, and benzo\[*b*\]furan scaffolds were resynthesized according to [@b0010]. These highly functionalized complex molecules, with different pharmacophores, may have potential applications in diverse, and economically relevant areas.

2. Materials and methods {#s0010}
========================

The target compounds were resynthesized in accordance with a previous article ([@b0010]). Additionally, all enzymatic assays and the molecular docking studies details have been provided in the [supplementary information](#s0060){ref-type="sec"}.

3. Results and discussion {#s0015}
=========================

3.1. Preparation of **5a-r** {#s0020}
----------------------------

A number of spirooxindole benzo\[*b*\]furan scaffolds were resynthesized using the 1,3-dipolar cycloaddition reaction method. As shown in [Fig. 2](#f0010){ref-type="fig"}, the synthetic pathway consist of the reaction of chalcone **2a-f** with dicarbonyl compounds (isatin, 5-chloroisatin, and 5-bromoisatin **3a-c**) and amino acids including (*S*)-thiazolidine-4-carboxylic acid or (2*S*,3a*S*,7a*S*)-octahydro-1*H*-indole-2-carboxylic acid. In this manner, a number of spirooxindole based benzo\[*b*\]furan scaffolds (**5a-r)** were obtained in high analytical purity with complete stereoselective reaction ([Scheme 1](#f0025){ref-type="fig"}). The synthetic methodology was carried out under mild alcoholic conditions, which is considered an eco-friendly approach. The general reaction is shown below, as variations of all three reactants are possible. The mechanism of cyclization is in accordance to previously established methods ([@b0095], [@b0030], [@b0115], [@b0110]).Fig. 2(**A**) Hydrophobic interactions embed compound **5i** inside COX-1 receptor (ID: 5WBE). (**B**) Hydrophobic interactions embed compound **5i** inside COX-2 receptor (ID: 3LN1). (**C**) Compound **5i** is overlaid with celecoxib inside COX-2 receptor (ID: 3LN1). (**D**) Compound **5a** with (ID: 5WBE) docked outside the receptor through formation of two HBs with ARG 120.Scheme 1The resynthesized compounds **5a-r.**

3.2. In vitro biological activity evaluation {#s0025}
--------------------------------------------

### 3.2.1. COX-1 and COX-2 inhibitors {#s0030}

The COX inhibitory activity of resynthesized target compounds were screened *in vitro* for the two isoforms of COX ([@b0005]). COX (COX-1, and COX-2) at 40 μ*g/*mL and the results obtained were shown in [Table 1](#t0005){ref-type="table"}. The IC~50~ values were determined, and the data are summarized in [Table 1](#t0005){ref-type="table"}. The data in [Table 1](#t0005){ref-type="table"} suggested that compounds **5a, 5c, 5h, 5i, 5l**, and **5p** possessed powerful COX-1 inhibitory abilities ranging from 40.81−83.4%. On the other hand, the inhibition of COX-2 was weaker, and was shown in the range of 1.11--20.56%. Indomethacin, acetyl-keto boswellic acid (AKBA), acetyl-*β*-boswellic acid, acetyl-*α*-boswellic acid, and *β*-boswellic acid were used as positive controls for COX-1. Celecoxib was used as a positive control for COX-2. In the case of COX-1 inhibition, the IC~50~ values recorded for the most active compounds were in the range of 20.42--38 µM; these included **5a, 5c, 5h, 5i, 5l**, and **5p**. Compound **5a** (IC~50~ = 20.42 µM) exhibited the strongest inhibition of COX-1 between these series. It was observed that the analogs were less selective against COX-2 than against COX-1.Table 1Results of percentage of inhibition of COX-1, and COX-2, IC~50~, selectivity COX-1/CO-2; percentage of inhibition of IL-6 (pg/ml), and TNF-α of the synthesized spirooxindoles based on benzo\[*b*\]furan scaffold **5a-r**.\#CompoundCOX-1%COX-2%COX-1COX-2Selectivity^b^\
IC~50~ COX-1/IC~50~ COX-2IL-6 (pg/ml)%TNF-α\
(pg/ml)%IC~50~ (*μ*M ± SD)[a](#tblfn1){ref-type="table-fn"}1![](fx1.gif)57.3811.2420.42 ± 0.5588.09 ± 1.7823%57.3851.242![](fx2.gif)27.369.81ND^c^NDND27.369.813![](fx3.gif)40.818.3337 ± 1.5476.17 ± 1.4649%59.8148.334![](fx4.gif)19.817.77NDNDND76.8167.775![](fx5.gif)9.431.8NDNDND82.4371.86![](fx6.gif)32.085.92NDNDND63.0855.927![](fx7.gif)19.812.76NDNDND81.8178.768![](fx8.gif)41.709.835.70 ± 0.5184.66 ± 1.1642%38.7049.89![](fx9.gif)44.5317.8529.55 ± 0.1971.25 ± 1.2941%62.5357.8510![](fx10.gif)21.707.89NDNDND77.7067.8911![](fx11.gif)12.264.45NDNDND87.2674.4512![](fx12.gif)47.7419.7831.25 ± 0.2458.75 ± 1.5836%42.7439.7813![](fx13.gif)20.755.78NDNDND79.5475.7814![](fx14.gif)9.431.11NDNDND82.1277.1115![](fx15.gif)29.256.11NDNDND76.8166.1116![](fx16.gif)52.759.9838.24 ± 0.9685.70 ± 1.5145%47.1839.9817![](fx17.gif)32.0810.1NDNDND67.4360.118![](fx18.gif)32.086.91NDNDND64.8162.91**STD**Indomethacin87.3118.760.24 ± 0.053.28 ± 0.097%7.78.1Acetyl-keto boswellic acid71.4219.877.84 ± 0.1382.52 ± 0.6210%7.3118.76Acetyl-*β*-boswellic acid75.7314.878.16 ± 0.1072.52 ± 0.5111%11.4219.87Acetyl-*α*-boswellic acid69.817.9810.13 ± 0.17\>10010%15.7314.87*β*-Boswellic acid64.777.6618.14 ± 0.42\>10018%19.8127.98Celecoxib8.79229.19 ± 0.330.08 ± 0.44365%24.7725.16Lipopolysaccharide (LPS)----------100100[^1]

### 3.2.2. Inhibition of TNF-α and IL-6 release in LPS-stimulated cells {#s0035}

The inhibitory activity of the resynthesized compounds was examined against LPS-induced TNF-α, and IL-6 in WI-38 fibroblast cells. All the examined compounds inhibited LPS-induced TNF-α, and IL-6 expression to different extents. Compounds **5d**, **5e**, **5f**, **5g**, and **5k** were the most effective among this compounds ([Table 1](#t0005){ref-type="table"}).

3.3. Docking study {#s0040}
------------------

The studied compounds were subjected to molecular docking study to evaluate their activities as anti-inflammatory agents by analyzing their ability to inhibit COX-1 (PDB: ID 5wbe ([@b0125]), and PDB: ID 1pgf ([@b0185]), COX-2 (PDB: ID 3ln1) ([@b0090]), and TNF-α (PDB: ID 2az5) ([@b0185]). Moreover, COX-1/COX-2 selectivity was explained.

The docking mode of final compounds with COX-1(PDB: ID 5wbe) ([@b0045]) showed that these compounds could be classified into two groups: Group (a) of compounds which interact with the protein inside the specific receptor of standards such as compound **5i** ([Fig. 2](#f0010){ref-type="fig"}A--C), and the second group (b) of compounds where the standard ligand docked outside the receptor through formation of hydrogen bonding (HB) interaction such as compound **5a** ([Fig. 2](#f0010){ref-type="fig"}D).

Compound **5i** interacts with key residues of COX-1, and COX-2 receptors *via* hydrophobic interactions through the benzofuran, indole, and *p*-bromophenyl moieties, [Fig. 2](#f0010){ref-type="fig"}A, and B respectively. Compound **5i** is overlaid with celecoxib inside the COX-2 receptor (ID: 3LN1). Biological studies revealed that both compounds (**5i** and **5p**) are non-selective. This were clarified by their ability to adapt inside the receptors of both COX-1 and COX-2 using the same binding mode (hydrophobic interactions) ([Fig. 2](#f0010){ref-type="fig"}A--D). Compound **5a** from the group (b) interacts with the receptor by formation of two HBs with Arg:120A via the oxygen of benzofuran moiety. This strong interaction helps to understand their selectivity.

The docking of the most active compounds with TNF-α (PDB: ID 2az5) was then studied. The standard ligand docked inside the receptor in a U-shape through the formation of hydrophobic interactions, [Fig. 3](#f0015){ref-type="fig"}A.Fig. 3**(A)** Standard drug co-crystallized with (ID: 2az5) through the formation of hydrophobic-hydrophobic interactions. (**B**) Compound **5a** with (ID: 2az5) docked outside the receptor through the formation of hydrophobic-hydrophobic interactions. **(C)** Compound **5a** with (ID: 2az5) docked with receptor overlay with standard drugs through the formation of hydrophobic-hydrophobic interactions.

Compound **5a** docked inside the receptor through the formation of hydrophobic-hydrophobic interactions. Moreover, it overlaid onto the standard drug via similar interactions with the receptor cleft, [Fig. 3](#f0015){ref-type="fig"}(B, C).

3.4. Structure activity relationship {#s0045}
------------------------------------

The structure activity relationship (SAR) of the studied compounds, and their biological activities with COX-1, COX-2, and the release of IL-6, and TNF-α were evaluated. The data presented in [Tables 1](#t0005){ref-type="table"}, and [Fig. 4](#f0020){ref-type="fig"} demonstrate that:(i)Compounds **5a, 5c, 5h, 5i, 5l**, and **5p** which were synthesized based on the thiazole amino acid rather than fused cyclohexane-proline, lead to better inhibition of COX-1, COX-2, IL-6, and TNF-α. This could be due to the geometry of the chair form, and its role in positioning benzofuran inside the receptor.(ii)Compound **5a,** with a chlorine atom on the oxindole moiety, and an un-substituted benzene on the benzoyl nucleus, showed the best, and selective results with 57.38% inhibition and IC~50~ = 20.42 ± 0.55 µM against COX-1 compared to the standard drug, celecoxib (8.7% inhibition and IC~50~ = 29.19 ± 0.33 µM).(iii)Compound **5c,** with a chlorine atom on the oxindole moiety, and *para* fluoro-substituted benzene on the benzoyl nucleus, showed good inhibition with 40.81% and IC~50~ = 37 ± 1.54 µM against COX-1, on the other hands when the chlorine and fluorine atoms replaced with bromine there is not dramatically changes in the activity which has been shown slightly more inhibition with 41.70% and IC~50~ = 35.70 ± 0.51 µM but when chlorine combined with bromine in the hit **5i** shown better activity (44.53% with IC~50~ = 29.55 ± 0.19 µM) than **5c** and **5 h.**(iv)Hits **5 l** (*para*-CF~3~), and **5p** (*para*-Cl) with the 5-chlorooxindole moiety, the percentage of inhibition increases and the IC~50~ decreases respectively.(v)Compound **5i**, with a chlorine atom on the oxindole moiety and a bromo-substituted benzene on the benzoyl nucleus, showed the best results with 62.53% inhibition of IL-6 compared to the standard drug, celecoxib (7.7% inhibition).(vi)The benzofuran core structure plays a crucial rule in binding to the receptor via the formation of hydrogen bonds with the oxygen atom.Fig. 4SAR of the studied compounds **5a-r.**

4. Conclusions {#s0050}
==============

The studied compounds **5a-r** were resynthesized and evaluated *in vitro* against COX-1, and COX-2 enzymes. The *in vitro* assay results revealed that compounds **5a, 5c, 5h, 5i, 5l**, and **5p** fixed with a substituted (aryl or oxoindole) moiety were the most potent and selective for COX-1 inhibitor with IC~50~ values ranging between 20.42 and 38.24 µM. Additionally, compounds **5d**, **5e**, **5f**, **5g**, and **5k** showed high potency against the release of pro-inflammatory cytokines such as IL-6, and TNF-α. The docking study reinforced the importance of the benzofuran moiety in the binding interaction especially through the formation of HB with receptors. This study illustrated that these could be useful lead compounds in the development of more potent and selective anti-inflammatory agents. Further *in vivo* studies will be considered for better understanding.
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[^1]: COX-1, and COX-2 inhibitory activity is expressed as the mean ± SD of triplicate experiments. ^b^Selectivity is defined as IC~50~ COX-1/IC~50~ COX-2. ^c^ND: not determined.
